Addex founder launches first Swiss spin-out from Merck Serono
This article was originally published in Scrip
François Conquet, the co-founder and former CEO of Addex Therapeutics, is to head a new company, Prexton Therapeutics, which is to be spun out of the soon-to-be-closed Geneva operations of Merck Serono.
You may also be interested in...
Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.